Developer docs
API playgroundTry for free, no card

Search company profiles

RenalGuard Solutions

Full company profile

uuid00038ek

Namestring
RenalGuard Solutions
Legal namestring
CardioRenal Systems, Inc.
Websiteurl
renalguard.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RenalGuard Solutions, operating as CardioRenal Systems, Inc., is a private, pre-commercial medical device company headquartered at 459 Fortune Boulevard, Milford, Massachusetts (founded 2013, 11–50 employees). It develops the RenalPro system — branded RenalGuard outside the United States — an FDA-designated Breakthrough Device that autonomously bundles fluid management and therapeutic delivery to prevent Acute Kidney Injury (AKI). The platform responds in real time to minute fluctuations in patient urine output and adjusts IV fluid administration in one-milliliter increments to maintain hemodynamic stability, with clinical evidence anchored by a 220-patient UK randomized controlled trial (Heyman Luckraz et al., European Journal of Cardio-Thoracic Surgery, March 2021) demonstrating a 52% reduction in AKI versus standard care and zero reported adverse events. The intended clinical settings are cardiac surgery programs (primary), cardiac catheterization labs (Contrast-Associated AKI), and intensive care units, addressing a US burden of approximately 3.1 million AKI cases and 285,000 deaths annually.

The company is pre-revenue in the United States, where the system is available only for investigational use under applicable regulatory guidelines, and is CE-marked for Fluid Balance Management outside the US. The anticipated revenue model post-clearance is hardware-led: capital equipment placement to hospitals paired with single-use disposables and service contracts, sold through a direct enterprise field-sales motion that engages hospital value analysis committees, cardiac surgeons, and nephrologists. Marketing is clinical-evidence-led, leveraging peer-reviewed publications and medical conferences rather than conventional sales motions, and the company holds EN ISO 13485:2016 certification (expiring July 31, 2027) covering design, development, and distribution.

RenalGuard has raised $21.5M across two disclosed Series 2 rounds (March 2017: $14.5M; September 2018: $7M led by Abiomed). Leadership disclosed includes Andrew Halpert as Chief Technology Officer and Greg Mann as Managing Director and Chief Financial Officer; no further management team detail is publicly available.

Short descriptiontext

RenalGuard Solutions (CardioRenal Systems) is a pre-commercial medical device company developing the RenalPro/RenalGuard system, an FDA Breakthrough Device that autonomously manages IV fluids in real time to prevent Acute Kidney Injury in cardiac surgery, cath lab, and ICU settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilford, United States
HQ citystring
Milford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
acute kidney injury prevention, fluid management systems, cardiac surgery devices, contrast-induced nephropathy, medical device therapy
Industry1 code
PRIMARYHLAHADAK
Suction, Irrigation & Fluid Management Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Acute Kidney Injury Prevention Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Post-Regulatory Clearance)
TypeHardware Sales
Description

Once FDA clearance is obtained, RenalGuard/CardiRenal Systems is expected to generate revenue through the sale or lease of RenalPro systems to hospitals, along with associated consumables and support services. The company currently operates in an investigational use phase, with the device available only through clinical studies and research settings under applicable regulatory guidelines. Revenue streams will likely include capital equipment placement, single-use disposables, and potential service/maintenance contracts.

cardiorenalsystems.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RenalPro
Description

FDA designated breakthrough device technology for preventing Acute Kidney Injury (AKI). Autonomously bundles fluid management and therapeutic systems. Available inside the US market.

cardiorenalsystems.com
+1 more record
Core offering1 text field

RenalGuard Solutions develops and sells the RenalPro/RenalGuard System, a proprietary medical device that autonomously bundles fluid management and therapeutic delivery to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery, cardiac catheterization, and ICU care. The system uses a urine output-responsive mechanism that balances IV fluid administration in real time, and is sold internationally under the RenalGuard brand with CE Mark while remaining investigational in the U.S.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 52% reduction in AKI incidence vs standard care in 220-patient randomized controlled trial (UK study, Heyman Luckraz et al., European Journal of Cardio-Thoracic Surgery, March 2021)
+2 more records
Product overview1 text field

RenalGuard Solutions (CardioRenal Systems) offers a single unified medical device system branded as RenalPro in the US and RenalGuard internationally. The core RenalPro/RenalGuard System provides FDA-designated breakthrough technology for acute kidney injury (AKI) prevention, combining fluid management with therapeutic delivery capabilities. RenalPro Therapy is the treatment protocol delivered by this system. The system is designed for multiple clinical settings including cardiac surgery (CSA-AKI), contrast procedures (CA-AKI), and ICU environments.

Product and service1 record
1RenalPro/RenalGuard System & Therapy
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Outset Medical (NASDAQ: OM) commercializes the Tablo Hemodialysis System, a direct peer in compact, easy-to-deploy renal care devices. Both companies target decentralized/point-of-care renal treatment and share similar hospital procurement and value analysis committee pathways.

TypeBroad incumbent
Description

Fresenius Medical Care is the global leader in dialysis products and services, including renal therapies and NxStage home hemodialysis. As a broad incumbent in renal care, it competes for hospital fluid management and renal therapy budgets and represents the dominant incumbent RenalGuard would compete against or partner with for distribution.

TypeBroad incumbent
Description

Baxter is a major medical device and pharmaceutical company with deep presence in renal therapies (peritoneal dialysis, hemodialysis) and IV infusion/ fluid management. Baxter overlaps with RenalPro's fluid delivery and renal care end markets, and its scale represents both competitive and partnership implications.

TypeBroad incumbent
Description

B. Braun is a global medical device and pharmaceutical company with significant IV infusion therapy, fluid management, and renal care offerings. Its infusion pump portfolio overlaps with the IV fluid administration component of RenalPro's value proposition in hospital settings.

TypeBroad incumbent
Description

ICU Medical is a specialist in IV infusion pumps, IV consumables, and critical care medical devices. It competes in the same hospital infusion therapy and fluid management procurement category as RenalPro and represents a plausible incumbent or acquisition target for RenalGuard.

TypeBroad incumbent
Description

Terumo manufactures medical devices including infusion systems, blood management, and cardiovascular products. Its hospital infusion portfolio overlaps with RenalPro's IV fluid administration mechanism, particularly in cardiac surgery and critical care settings.

TypeOthers
Description

Edwards Lifesciences is a leader in cardiac surgery and critical care monitoring, including hemodynamic monitoring technologies used in cardiac surgery and ICU. While not a fluid management peer, Edwards sells into the same cardiac surgery and ICU customer base and represents both a potential partner and an adjacent strategic acquirer.

TypeOthers
Description

Medtronic is the largest medical device company globally, with strong positions in cardiac surgery, perfusion, and patient monitoring. While not a fluid management peer, Medtronic's relationships with cardiac surgeons and perfusionists create a strategic adjacency and potential acquisition angle for RenalGuard.

TypeEmerging player
Description

Spectral Medical is developing PMX (polymyxin B hemoperfusion) for endotoxemia and septic AKI in the ICU. As an emerging player in AKI prevention/treatment in critical care, Spectral targets an overlapping patient population (ICU AKI) using a different therapeutic modality, making it a relevant emerging peer.

TypeRegional player
Description

Chiesi Group is a multinational pharmaceutical company headquartered in Italy with historical involvement in the RenalGuard franchise in Europe. As a potential or prior licensee/distributor of the RenalGuard system in select international markets, Chiesi represents a relevant regional/commercial peer rather than a device competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RenalGuard Solutions

Acute Kidney Injury Prevention Medical Devicesrenalguard.com

RenalGuard Solutions (CardioRenal Systems) is a pre-commercial medical device company developing the RenalPro/RenalGuard system, an FDA Breakthrough Device that autonomously manages IV fluids in real time to prevent Acute Kidney Injury in cardiac surgery, cath lab, and ICU settings.

What RenalGuard Solutions does

RenalGuard Solutions, operating as CardioRenal Systems, Inc., is a private, pre-commercial medical device company headquartered at 459 Fortune Boulevard, Milford, Massachusetts (founded 2013, 11–50 employees). It develops the RenalPro system — branded RenalGuard outside the United States — an FDA-designated Breakthrough Device that autonomously bundles fluid management and therapeutic delivery to prevent Acute Kidney Injury (AKI). The platform responds in real time to minute fluctuations in patient urine output and adjusts IV fluid administration in one-milliliter increments to maintain hemodynamic stability, with clinical evidence anchored by a 220-patient UK randomized controlled trial (Heyman Luckraz et al., European Journal of Cardio-Thoracic Surgery, March 2021) demonstrating a 52% reduction in AKI versus standard care and zero reported adverse events. The intended clinical settings are cardiac surgery programs (primary), cardiac catheterization labs (Contrast-Associated AKI), and intensive care units, addressing a US burden of approximately 3.1 million AKI cases and 285,000 deaths annually.

The company is pre-revenue in the United States, where the system is available only for investigational use under applicable regulatory guidelines, and is CE-marked for Fluid Balance Management outside the US. The anticipated revenue model post-clearance is hardware-led: capital equipment placement to hospitals paired with single-use disposables and service contracts, sold through a direct enterprise field-sales motion that engages hospital value analysis committees, cardiac surgeons, and nephrologists. Marketing is clinical-evidence-led, leveraging peer-reviewed publications and medical conferences rather than conventional sales motions, and the company holds EN ISO 13485:2016 certification (expiring July 31, 2027) covering design, development, and distribution.

RenalGuard has raised $21.5M across two disclosed Series 2 rounds (March 2017: $14.5M; September 2018: $7M led by Abiomed). Leadership disclosed includes Andrew Halpert as Chief Technology Officer and Greg Mann as Managing Director and Chief Financial Officer; no further management team detail is publicly available.

RenalGuard Solutions firmographics

Firmographics
Name
RenalGuard Solutions
Legal name
CardioRenal Systems, Inc.
Website
https://renalguard.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
RenalGuard Solutions (CardioRenal Systems) is a pre-commercial medical device company developing the RenalPro/RenalGuard system, an FDA Breakthrough Device that autonomously manages IV fluids in real time to prevent Acute Kidney Injury in cardiac surgery, cath lab, and ICU settings.
Ownership category
akta.pro rank

RenalGuard Solutions industry classification

Industry
Product category
Acute Kidney Injury Prevention Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAK
Suction, Irrigation & Fluid Management Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Acute kidney injury prevention
  • Fluid management systems
  • Cardiac surgery devices
  • Contrast-induced nephropathy
  • Medical device therapy

Where RenalGuard Solutions is headquartered

Location

Headquarters

HQ city
Milford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RenalGuard Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (Post-Regulatory Clearance): Once FDA clearance is obtained, RenalGuard/CardiRenal Systems is expected to generate revenue through the sale or lease of RenalPro systems to hospitals, along with associated consumables and support services. The company currently operates in an investigational use phase, with the device available only through clinical studies and research settings under applicable regulatory guidelines. Revenue streams will likely include capital equipment placement, single-use disposables, and potential service/maintenance contracts.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

RenalGuard Solutions product offering

Product offering

Core offering

RenalGuard Solutions develops and sells the RenalPro/RenalGuard System, a proprietary medical device that autonomously bundles fluid management and therapeutic delivery to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery, cardiac catheterization, and ICU care. The system uses a urine output-responsive mechanism that balances IV fluid administration in real time, and is sold internationally under the RenalGuard brand with CE Mark while remaining investigational in the U.S.

Product overview

RenalGuard Solutions (CardioRenal Systems) offers a single unified medical device system branded as RenalPro in the US and RenalGuard internationally. The core RenalPro/RenalGuard System provides FDA-designated breakthrough technology for acute kidney injury (AKI) prevention, combining fluid management with therapeutic delivery capabilities. RenalPro Therapy is the treatment protocol delivered by this system. The system is designed for multiple clinical settings including cardiac surgery (CSA-AKI), contrast procedures (CA-AKI), and ICU environments.

Differentiator

Problem solved

Functional benefit

Brands

  • RenalPro: FDA designated breakthrough device technology for preventing Acute Kidney Injury (AKI). Autonomously bundles fluid management and therapeutic systems. Available inside the US market.
  • RenalGuard

Products and services

  • RenalPro/RenalGuard System & Therapy

Quantifiable outcome

  • 52% reduction in AKI incidence vs standard care in 220-patient randomized controlled trial (UK study, Heyman Luckraz et al., European Journal of Cardio-Thoracic Surgery, March 2021)
  • +2 more outcomes

Companies that use RenalGuard Solutions

Customer profile

Segments3 records

Ideal customer profiles3 records

RenalGuard Solutions technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

RenalGuard Solutions partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

RenalGuard Solutions competitors and assessment

Company assessment

Direct peers

  • Outset Medical: Outset Medical (NASDAQ: OM) commercializes the Tablo Hemodialysis System, a direct peer in compact, easy-to-deploy renal care devices. Both companies target decentralized/point-of-care renal treatment and share similar hospital procurement and value analysis committee pathways.

Broad incumbents

  • Fresenius Medical Care: Fresenius Medical Care is the global leader in dialysis products and services, including renal therapies and NxStage home hemodialysis. As a broad incumbent in renal care, it competes for hospital fluid management and renal therapy budgets and represents the dominant incumbent RenalGuard would compete against or partner with for distribution.
  • Baxter International: Baxter is a major medical device and pharmaceutical company with deep presence in renal therapies (peritoneal dialysis, hemodialysis) and IV infusion/ fluid management. Baxter overlaps with RenalPro's fluid delivery and renal care end markets, and its scale represents both competitive and partnership implications.
  • B. Braun Medical: B. Braun is a global medical device and pharmaceutical company with significant IV infusion therapy, fluid management, and renal care offerings. Its infusion pump portfolio overlaps with the IV fluid administration component of RenalPro's value proposition in hospital settings.
  • ICU Medical: ICU Medical is a specialist in IV infusion pumps, IV consumables, and critical care medical devices. It competes in the same hospital infusion therapy and fluid management procurement category as RenalPro and represents a plausible incumbent or acquisition target for RenalGuard.
  • Terumo Medical: Terumo manufactures medical devices including infusion systems, blood management, and cardiovascular products. Its hospital infusion portfolio overlaps with RenalPro's IV fluid administration mechanism, particularly in cardiac surgery and critical care settings.

Others

  • Edwards Lifesciences: Edwards Lifesciences is a leader in cardiac surgery and critical care monitoring, including hemodynamic monitoring technologies used in cardiac surgery and ICU. While not a fluid management peer, Edwards sells into the same cardiac surgery and ICU customer base and represents both a potential partner and an adjacent strategic acquirer.
  • Medtronic: Medtronic is the largest medical device company globally, with strong positions in cardiac surgery, perfusion, and patient monitoring. While not a fluid management peer, Medtronic's relationships with cardiac surgeons and perfusionists create a strategic adjacency and potential acquisition angle for RenalGuard.

Emerging players

  • Spectral Medical: Spectral Medical is developing PMX (polymyxin B hemoperfusion) for endotoxemia and septic AKI in the ICU. As an emerging player in AKI prevention/treatment in critical care, Spectral targets an overlapping patient population (ICU AKI) using a different therapeutic modality, making it a relevant emerging peer.

Regional players

  • Chiesi Group: Chiesi Group is a multinational pharmaceutical company headquartered in Italy with historical involvement in the RenalGuard franchise in Europe. As a potential or prior licensee/distributor of the RenalGuard system in select international markets, Chiesi represents a relevant regional/commercial peer rather than a device competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

RenalGuard Solutions social profiles

Digital presence

RenalGuard Solutions compliance and trust

Trust signal

Compliance2 records

RenalGuard Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RenalGuard Solutions leadership team

Management profile

Number of profiles

Profiles2 records

RenalGuard Solutions funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RenalGuard Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RenalGuard Solutions

What does RenalGuard Solutions do?

RenalGuard Solutions develops and sells the RenalPro/RenalGuard System, a proprietary medical device that autonomously bundles fluid management and therapeutic delivery to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery, cardiac catheterization, and ICU care. The system uses a urine output-responsive mechanism that balances IV fluid administration in real time, and is sold internationally under the RenalGuard brand with CE Mark while remaining investigational in the U.S.

Is RenalGuard Solutions a public or private company?

RenalGuard Solutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was RenalGuard Solutions founded?

RenalGuard Solutions was founded in 2013. It employs 11 to 50 people.

Where is RenalGuard Solutions based?

RenalGuard Solutions is headquartered in Milford, United States, in the North America region.

How does RenalGuard Solutions make money?

One revenue line is on record: medical Device Sales (Post-Regulatory Clearance).

Who are RenalGuard Solutions's main competitors?

Outset Medical is listed as a direct peer. Broad incumbents are Fresenius Medical Care, Baxter International, B. Braun Medical, ICU Medical and Terumo Medical. Others are Edwards Lifesciences and Medtronic. Spectral Medical is listed as an emerging player. Chiesi Group is listed as a regional player.

Does RenalGuard Solutions have an API?

No public API is recorded for RenalGuard Solutions.

What industry is RenalGuard Solutions in?

RenalGuard Solutions's product category is Acute Kidney Injury Prevention Medical Devices. Its primary akta.pro industry code is HLAHADAK, Suction, Irrigation & Fluid Management Systems. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals